Literature DB >> 7285488

Diethylcarbamazine disposition in patients with onchocerciasis.

G Edwards, K Awadzi, A M Breckenridge, H M Gilles, M L Orme, S A Ward.   

Abstract

Diethylcarbamazine (DEC), 0.5 mg/kg, was taken orally by six patients being treated for onchocerciasis. Blood samples were taken at timed intervals for 48 hr and urine and feces collected for 4 days. Plasma and urinary concentrations of DEC and DEC N-oxide were measured by gas-liquid chromatography. DEC appeared to be rapidly absorbed, with a peak plasma concentration of 150 to 250 ng/ml reached in 2 to 3 hr. There was a secondary rise in plasma DEC concentration at 5 to 6 hr in all patients. In contrast to the way the drug is eliminated in rats, in man it was by both renal and extrarenal routes, with small amounts (+/- 10%) being excreted as an N-oxide metabolite. DEC kinetics were also investigated in five normal subjects and the result were much the same. Clinical implications are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7285488     DOI: 10.1038/clpt.1981.202

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Diethylcarbamazine in the treatment of patients with onchocerciasis.

Authors:  K Awadzi; H M Gilles
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of anthelmintic drugs.

Authors:  G Edwards; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

3.  The effect of moderate urine alkalinisation on low dose diethylcarbamazine therapy in patients with onchocerciasis.

Authors:  K Awadzi; K K Adjepon-Yamoah; G Edwards; M L Orme; A M Breckenridge; H M Gilles
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

4.  The effect of renal disease on the pharmacokinetics of diethylcarbamazine in man.

Authors:  K K Adjepon-Yamoah; G Edwards; A M Breckenridge; M L Orme; S A Ward
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

5.  [Experimental filariasis in Proechimys oris by Dipetalonema dessetae. 5. Effect of parasitism on metabolism of diethylcarbamazine].

Authors:  F Kani; M C Dessalles; C Jacquot; G Mahuzier; P Gayral
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Jul-Sep       Impact factor: 2.441

Review 6.  Antiparasitic drugs in children.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.

Authors:  G Edwards; P A Winstanley; S A Ward
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

8.  Diagnosis of O. volvulus infection via skin exposure to diethylcarbamazine: clinical evaluation of a transdermal delivery technology-based patch.

Authors:  K Awadzi; Nicholas O Opoku; Simon K Attah; Janis K Lazdins-Helds; Annette C Kuesel
Journal:  Parasit Vectors       Date:  2015-10-09       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.